Mylan B.V.

Mylan B.V. is a subsidiary of Mylan Inc. since the 2^nd of October 2007.
After a substantial growth we now have over 350 presentations. Every year we launch more generic medicines for a competitive price. To achieve this, we make use of the benefits provided by being part of an international organisation, such as global development, consolidated production and high quality standards.
We have achieved a top 5 position amongst the Dutch generic companies, despite the fact that we are a relatively young player on the Dutch market.

Who is Mylan Inc.?

Mylan is the third largest generic pharmaceutical company in the world. We hold top-five positions in 13 different established markets worldwide and are building a strong presence in many emerging generics markets.
Today, Mylan markets more than 570 products to consumers in more than 90 countries across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
We also have the deepest pipeline and largest number of products pending regulatory approval in company history.

Mylan focuses on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and enjoys a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products.

Mylan operates through three principal subsidiaries: Mylan Pharmaceuticals, a world leader in generic pharmaceuticals; Mylan Technologies, the largest producer of generic and branded transdermal patches for the U.S. market; and UDL Laboratories, the top U.S.-supplier of unit dose pharmaceuticals.
Through its controlling interest in Matrix Laboratories, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world.